Landmark 2026 Clinical Study Validates At-Home Quantitative Multi-Hormone Monitoring Against Ultrasound Gold Standard
Landmark 2026 Clinical Study Validates At-Home Quantitative Multi-Hormone Monitoring Against Ultrasound Gold Standard
PR Newswire
SAN FRANCISCO, Sept. 1, 2026
A peer-reviewed study published in Reproductive BioMedicine Online demonstrates 96% agreement between Mira at-home LH measurements and transvaginal ultrasound, marking a major milestone in decentralized reproductive care.
SAN FRANCISCO, Sept. 1, 2026 /PRNewswire/ -- A landmark clinical study published in Reproductive BioMedicine Online (Bouchard et al., 2026) provides strong diagnostic accuracy validation for at-home quantitative multi-hormone tracking, establishing a major milestone in reproductive healthcare and FemTech.
The prospective 18-month, STARD-compliant diagnostic accuracy study evaluated the Mira at-home hormone monitor across 121 ovulatory cycles and 890 transvaginal ultrasound scans, comparing quantitative urine testing against the clinical gold standards of ultrasound-confirmed ovulation and serum blood draws. Results showed that ovulation occurred within ±1 day of the Mira luteinizing hormone (LH) peak in 96% of ovulatory cycles (R² = 0.96, P < 0.001).
This research updates 25-year-old industry benchmarks by offering the first STARD-compliant, blinded ultrasound validation of a quantitative four-hormone monitor (measuring LH, E13G/estrogen, PDG/progesterone, and FSH).
Key Study Findings & Clinical Data Highlights
- 96% Precision with Ultrasound Gold Standard: The day of ovulation confirmed by serial transvaginal ultrasound aligned within ±1 day of the LH peak measured by the Mira monitor in 96% of cycles, with an intraclass correlation coefficient of 0.971.
- Strong Correlation with Blood Serum Levels: First-morning urine hormone profiles closely mirrored serum blood draws collected within 90 minutes, including LH (R² = 0.92), progesterone metabolite PDG (R² = 0.75), estrogen metabolite E13G (R² = 0.73), and FSH (R² = 0.61).
- Biological Variability Beyond Calendar Estimates: Even among women with regular periods, 11% of cycles were anovulatory. Additionally, 12.4% of ovulations occurred while LH levels were still rising, underscoring why tracking continuous multi-hormone patterns offers clearer visibility than single-day binary LH tests or date-based app algorithms.
- Earlier Fertile Window Identification: Urinary estrogen (E13G) signals rose approximately 5 to 6 days prior to ovulation, capturing real ovarian follicle development to identify the fertile window earlier than LH tracking alone.
Executive & Expert Commentary
Dr. Thomas P. Bouchard, MD, Lead Author and Clinical Researcher:
"For over two decades, at-home fertility tracking was based on qualitative indicators without providing quantitative hormone values. By evaluating quantitative four-hormone tracking against 890 ultrasound scans with a blinded, STARD-compliant ultrasound protocol, this study establishes rigorous clinical and research benchmarks for at-home ovulation prediction and confirmation."
Sylvia Kang, Founder and Chief Executive Officer of Mira:
"Women deserve precise biological data about their reproductive health without needing constant clinic visits and serial blood draws. This study validates that quantitative at-home testing delivers clinic-grade hormonal visibility, marking a transformative step forward for decentralized healthcare, fertility care, and personalized hormone monitoring."
Transforming Reproductive Healthcare & Decentralized Medicine
Traditional fertility monitoring often requires repeated clinic visits for serial serum blood draws and invasive follicular ultrasounds. The study authors concluded that validated, quantitative at-home urine hormone tracking supports broader clinical adoption, offering a reliable, non-invasive diagnostic tool that can reduce reliance on routine clinic visits while improving patient convenience and health literacy.
About Mira
Mira is an innovative women's health company providing the most advanced at-home hormone testing and tracking technology. By measuring exact numerical hormone concentrations, Mira empowers women with highly accurate, clinically-validated* data to navigate fertility, menopause, and overall hormonal health with confidence. Learn more at shop.miracare.com and join the conversation on TikTok, Instagram, and Facebook.
Media Contact
Mira@Brilliant-Agency.com
Study Citation: Bouchard et al., Reproductive BioMedicine Online (2026). DOI: 10.1016/j.rbmo.2026.105881
SOURCE Mira
The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
The 10 Best Companies to Invest in Now
14 Elite Funds and ETFs, and 5 Popular Funds That Just Missed the Mark
The Top Funds for a Simpler Retirement Portfolio
The 10 Best Dividend Stocks
United States